Oxford Drug Design
Robert is a founder and the CEO of Sentinel Oncology Ltd, a company dedicated towards the discovery of novel small molecules for the treatment of cancer. He is a medicinal chemist by background with over twenty-five years’ industrial experience. He has held positions at Pfizer (1993-1997); Cambridge Discovery Chemistry (1997-2000); Millennium Pharmaceuticals (200-2003); Astex Therapeutics (2003-2005) & Sentinel Oncology (2005-present).
As CEO & founder of Sentinel Oncology, he has successfully raised multiple rounds of funding, built a pipeline of small molecule drug assets and secured multiple licensing deals with Biotech and Pharma. Sentinel has been the recipient of numerous awards & grants for innovation and Robert is a named inventor on over 50 patents & publications describing the discovery and use of small molecules for the treatment of unmet medical needs.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Oxford Drug Design
Oxford Drug Design focuses on developing and delivering services and technologies in computer-aided drug discovery.